ReviewMolecules (Basel, Switzerland)2026
Oral Cavity Antibacterial Discovery Pipeline Driven by Advanced Analytical Techniques.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The oral cavity represents an extremely complex and dynamic microbial ecosystem capable of rapidly adapting to antimicrobial stress. These characteristics make it a promising environment for the identification of novel bioactive molecules with therapeutic potential. At the same time, the increasing prevalence of resistant pathogens in dental and oral-maxillofacial infections highlights the limitations of current therapeutic strategies and the urgent need for new effective antibacterial agents. This review examines the central role of advanced analytical techniques, with particular emphasis on mass spectrometry, in the discovery and characterization of bioactive metabolites and biomarkers relevant to future antibacterial discovery and to the understanding of biological responses to pathogens or therapeutic interventions. It discusses how the integration of metabolomics approaches, imaging mass spectrometry, and bioinformatics platforms is transforming the antibacterial discovery process by accelerating the identification of active compounds and improving the understanding of microbial interactions within the oral cavity. Overall, this work provides an up-to-date overview of current knowledge regarding the oral microbiome as a source of bioactive molecules and biomarkers. It highlights how emerging analytical technologies are opening new perspectives for the development of innovative therapeutic strategies against resistant oral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.